Scholarlink

<p>This study aimed to investigate the therapeutic potential of species from the Anacardiaceae family in experimental diabetes mellitus. The scoping review was conducted following the Joanna Briggs Institute (JBI) methodology and reported according to the PRISMA Extension for Scoping Reviews (PRISMA-ScR). The protocol was registered in the Open Science Framework (OSF), and the search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and EMBASE, as well as Google Scholar and ProQuest, with no language or publication date restrictions. Studies involving rodent models of experimental diabetes mellitus treated with species from the Anacardiaceae family were included. Exclusion criteria comprised studies involving non-rodent animals, studies not related to both Anacardiaceae and experimental diabetes mellitus, and those involving synthetic therapies already available on the market. Among the 51 articles evaluated, the first study associating the Anacardiaceae family with experimental diabetes mellitus was published in 2004. Streptozotocin was used in 62.7% of the studies, and species such as <i>Anacardium occidentale</i> (cashew) and <i>Mangifera indica</i> (mango) were the most frequently studied. Tissue analysis was performed in 47% of the studies, while biochemical analyses were carried out in 92%. In conclusion, species from the Anacardiaceae family demonstrate promising antidiabetic effects in experimental models, highlighting the therapeutic potential of Brazilian flora as a source of bioactive compounds for diabetes management. Further studies are needed to confirm their efficacy and safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic effects of the Anacardiaceae family on experimental diabetes mellitus: a scoping review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月4日

查看全文
  • Letícia Alves Borges e Pires,
  • Cecília Paulino Cassiano da Silva,
  • Vitória Natália Ferreira de Sena,
  • Bento João Abreu,
  • Flávio Santos Silva,
  • Karinna Veríssimo Meira Taveira,
  • Karina Carla de Paula Medeiros

摘要

This study aimed to investigate the therapeutic potential of species from the Anacardiaceae family in experimental diabetes mellitus. The scoping review was conducted following the Joanna Briggs Institute (JBI) methodology and reported according to the PRISMA Extension for Scoping Reviews (PRISMA-ScR). The protocol was registered in the Open Science Framework (OSF), and the search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and EMBASE, as well as Google Scholar and ProQuest, with no language or publication date restrictions. Studies involving rodent models of experimental diabetes mellitus treated with species from the Anacardiaceae family were included. Exclusion criteria comprised studies involving non-rodent animals, studies not related to both Anacardiaceae and experimental diabetes mellitus, and those involving synthetic therapies already available on the market. Among the 51 articles evaluated, the first study associating the Anacardiaceae family with experimental diabetes mellitus was published in 2004. Streptozotocin was used in 62.7% of the studies, and species such as Anacardium occidentale (cashew) and Mangifera indica (mango) were the most frequently studied. Tissue analysis was performed in 47% of the studies, while biochemical analyses were carried out in 92%. In conclusion, species from the Anacardiaceae family demonstrate promising antidiabetic effects in experimental models, highlighting the therapeutic potential of Brazilian flora as a source of bioactive compounds for diabetes management. Further studies are needed to confirm their efficacy and safety.